TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
31 hedge funds and large institutions have $14.6M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 6 closing their positions.
2,000% more call options, than puts
Call options by funds: $63K | Put options by funds: $3K
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
6% less funds holding
Funds holding: 33 → 31 (-2)
11% less capital invested
Capital invested by funds: $16.4M → $14.6M (-$1.81M)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$605K |
| 2 |
Renaissance Technologies
New York
|
+$102K |
| 3 |
VF
Virtu Financial
New York
|
+$68.5K |
| 4 |
CBA
Coastal Bridge Advisors
Westport,
Connecticut
|
+$15.1K |
| 5 |
BlackRock
New York
|
+$5.87K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$579K |
| 2 |
CL
CSS LLC
Chicago,
Illinois
|
-$76K |
| 3 |
Two Sigma Advisers
New York
|
-$71.8K |
| 4 |
Two Sigma Investments
New York
|
-$67K |
| 5 |
Millennium Management
New York
|
-$57K |
TCON Hedge Fund Activity: Q4 2022 in Review
31 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q4 2022, worth a combined $14.6M — down 11% from $16.4M a quarter earlier.
Fund positioning in TCON was balanced in Q4 2022: 6 funds opened new positions, 6 closed out, 5 added to existing stakes and 7 trimmed.
The largest buyer was Opaleye Management, adding an estimated $605K. The largest seller was NEA Management Company, exiting entirely with an estimated $579K sold.
- 31 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q4 2022, down from 33 in Q3 2022.
- Funds reported $14.6M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q4 2022, down 11% quarter-over-quarter.
- 6 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q4 2022 and 6 closed out, a net change of 0 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q4 2022 was Opaleye Management, an estimated $605K added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q4 2022 was NEA Management Company, an estimated $579K sold.
Based on aggregated 13F filings for Q4 2022.